{"prompt": "['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Laboratory', 'Parameters', 'Assessments', 'required for', 'phosphatase', 'screening)', 'Routine', 'Urinalysis', 'Specific gravity', 'pH, glucose, protein, blood, ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'Serum or urine human chorionic gonadotropin (hCG) pregnancy test (as', 'needed for women of childbearing potential)2', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody\u00b3', 'All study-required laboratory assessments will be performed by a central', 'laboratory, with the exception of urine testing', 'NOTES :', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', \"(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or\", 'cirrhosis).', '2. Local urine hCG testing will be standard for the protocol unless serum testing is required by local', 'regulation or IRB/IEC.', '3.', 'Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', '87']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amended text:', 'Table 8', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', 'required for', 'phosphatase', 'screening)', 'Routine', 'Urinalysis', 'Specific gravity', 'pH, glucose, protein, blood, ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody\u00b2', 'All study-required laboratory assessments will be performed by a central', 'laboratory', 'NOTES :', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', '88']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', \"(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or\", 'cirrhosis).', '2.', 'Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', 'Section 12.5 Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', 'Original text:', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', \"Note: Documentation can come from the site personnel's: review of participant's\", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female:', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level', 'in the postmenopausal range may be used to confirm a postmenopausal', 'state in women not using hormonal contraception or hormonal', 'replacement therapy (HRT). However, in the absence of 12 months of', 'amenorrhea, a single FSH measurement is insufficient.', 'Females on HRT and whose menopausal status is in doubt will be', 'required to use one of the non-hormonal highly effective contraception', 'methods if they wish to continue their HRT during the study. Otherwise,', 'they must discontinue HRT to allow confirmation of postmenopausal', 'status before study enrollment.', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle', '(abstinent on a long term and persistent basis) and agree to remain abstinent', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', '89']\n\n###\n\n", "completion": "END"}